Europe Next Generation Sequencing (NGS) Market: Analysis and Forecast, 2023-2033

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,950	128 Pages	BIS Research	January, 2024	BIS18466636

Best Price Guarantee
Price	from $2,950
Length	128 Pages
Publisher	BIS Research
Published Date	January, 2024
SKU	BIS18466636

Europe Next Generation Sequencing (NGS) Market: Analysis and Forecast, 2023-2033

Introduction to Europe Next Generation Sequencing (NGS) Market

The Europe NGS market was valued at $1.71 billion in 2023 and is expected to reach $5.72 billion by 2033, growing at a CAGR of 12.83% during the forecast period 2023-2033. The Next Generation Sequencing (NGS) market is experiencing growth primarily due to several key factors. These include the declining expenses associated with genome sequencing, the promising applications of NGS in oncology, the increasing prevalence of population-wide genomic research, governmental support for the integration of NGS in healthcare, and the superior attributes of NGS technology when compared to other sequencing methods.

Market Introduction

The Europe Next Generation Sequencing (NGS) market, specifically within the library preparation and sequencing segments, is witnessing substantial growth. Library preparation involves the crucial steps of DNA or RNA fragmentation, amplification, and indexing, making it a fundamental component of NGS workflows. In this context, the market is characterized by the increasing demand for high-throughput and efficient library preparation kits and systems, driven by the expanding applications of NGS in genomics research, clinical diagnostics, and personalized medicine.

The sequencing step, which follows library preparation, is equally significant. Europe's NGS market is marked by a rising adoption of advanced sequencing platforms, including Illumina and Oxford Nanopore technologies, owing to their ability to deliver accurate and rapid sequencing results. This growth is fueled by the escalating need for genomic analysis in various fields, such as healthcare, agriculture, and microbiology, highlighting the pivotal role of library preparation and sequencing products in advancing NGS capabilities in the European region.

Market Segmentation:

Segmentation 1: by Offering

Consumables
Library Preparation Kits
Sequencing Kits
Equipment
Services

Segmentation 2: by Throughput

High- and Ultra-High-Throughput
Medium-Throughput
Low-Throughput

Segmentation 3: by Technology Type

Sequencing by Synthesis
In Torrent Semiconductor Sequencing
Single Molecule Real-Time Sequencing
Nanopore Sequencing Technology
Other Technologies

Segmentation 4: by Application

Clinical Diagnostics
Oncology
Non-Oncology
Research
Oncology
Non-Oncology

Segmentation 5: by Country

Germany
U.K.
France
Italy
Spain
Rest-of-Europe

How can this report add value to an organization?

Type: The Europe NGS market has been segmented based on various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe NGS market is consolidated, with a few players accounting for most of the market share. Key players in the Europe NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Key Companies Profiled:

Oxford Nanopore Technologies plc
Qiagen N.V.
F. Hoffmann-La Roche Ltd
Centogene N.V.
Alithea Genomics

*PDF email from publisher allows for 1-3 users, with permission to print*

Please Note: It will take 1-5 business days to complete the report upon order confirmation.

Executive Summary: Scope of the Study; Research Methodology
1 Markets: 1.1 Market Outlook; 1.1.1 Product Definition; 1.1.2 Inclusion and Exclusion Criteria; 1.1.3 Key Findings; 1.2 Industry Outlook; 1.2.1 NGS: Overview; 1.2.2 Historical Trends; 1.2.3 Comparative Analysis of Various Technologies; 1.2.4 NGS Market: Overview; 1.2.5 Emerging NGS Technologies; 1.2.5.1 In-Situ Sequencing; 1.2.5.2 Microscopy-Based Sequencing; 1.2.5.3 Future of Ultra-High Throughput NGS; 1.2.6 Current Market Scenario; 1.2.6.1 For Researchers; 1.2.6.2 For Diagnostics; 1.2.7 COVID-19 Impact on the NGS Market; 1.2.8 Supply Chain Analysis; 1.2.8.1 Key Entities in Supply Chain; 1.2.9 Research Publications; 1.2.10 Primary Insights; 1.2.11 Pricing Analysis; 1.3 Business Dynamics; 1.3.1 Impact Analysis; 1.3.2 Business Drivers; 1.3.2.1 Decreasing Cost of Genome Sequencing; 1.3.2.2 Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings; 1.3.2.3 Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare; 1.3.2.4 Advantages of NGS Technology over Other Technologies; 1.3.3 Business Restraints; 1.3.3.1 Concerns Surrounding the Privacy of Patient Genomic Data; 1.3.3.2 Lack of Complete Reimbursement Coverage for NGS Testing; 1.3.4 Business Opportunities; 1.3.4.1 Evolving Regulatory Landscape for Clinical NGS; 1.3.4.2 Growing Number of Gene Mutations across Various Diseases
2 Europe: 2.1 Europe NGS Market; 2.1.1 Overview; 2.1.2 Legal Requirements and Framework in Europe; 2.1.3 Market Dynamics; 2.1.3.1 Impact Analysis; 2.1.4 Key Distributors; 2.1.5 Genome Projects; 2.1.6 Market Sizing and Forecast, by Value; 2.1.6.1 Europe NGS Market (by Offering), by Value; 2.1.6.1.1 Europe NGS Market (Equipment), by Value; 2.1.6.1.1.1 Europe NGS Market (Equipment, by Company), by Value; 2.1.6.1.1.1.1 Europe NGS Market (Equipment, by Illumina, Inc.), by Value; 2.1.6.1.1.1.2 Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value; 2.1.6.1.1.1.3 Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value; 2.1.6.1.1.1.4 Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value; 2.1.6.1.2 Europe NGS Market (Equipment), by Volume; 2.1.6.1.3 Europe NGS Market (by Throughput), by Value; 2.1.6.1.4 Europe NGS Market (by Throughput), by Volume; 2.1.6.2 Europe NGS Market (by End User); 2.1.6.2.1 Europe NGS Market (Academic and Research Institutes, by Offering); 2.1.6.2.2 Europe NGS Market (Clinical Laboratories, by Offering); 2.1.6.2.3 Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering); 2.1.6.2.4 Europe NGS Market (Other End Users, by Offering); 2.1.6.3 Europe NGS Market (by Technology Type); 2.1.6.4 Europe NGS Market (by Application); 2.1.6.4.1 Europe NGS Market (Application, by Clinical Diagnostics); 2.1.6.4.2 Europe NGS Market (Application, by Research); 2.1.6.5 Europe NGS Market (by Country); 2.1.6.5.1 Germany; 2.1.6.5.1.1 Market Dynamics; 2.1.6.5.1.2 Market Sizing and Forecast, by Value; 2.1.6.5.1.2.1 Germany NGS Market (by Offering), by Value; 2.1.6.5.1.2.1.1 Germany NGS Market (Equipment), by Value; 2.1.6.5.1.2.1.1.1 Germany NGS Market (Equipment, by Company), by Value; 2.1.6.5.1.2.1.2 Germany NGS Market (Equipment), by Volume; 2.1.6.5.2 U.K.; 2.1.6.5.2.1 Market Dynamics; 2.1.6.5.2.2 Market Sizing and Forecast, by Value; 2.1.6.5.2.2.1 U.K. NGS Market (by Offering), by Value; 2.1.6.5.2.2.1.1 U.K. NGS Market (Equipment), by Value; 2.1.6.5.2.2.1.1.1 U.K. NGS Market (Equipment, by Company), by Value; 2.1.6.5.2.2.1.2 U.K. NGS Market (Equipment), by Volume; 2.1.6.5.3 France; 2.1.6.5.3.1 Market Dynamics; 2.1.6.5.3.2 Market Sizing and Forecast, by Value; 2.1.6.5.3.2.1 France NGS Market (by Offering), by Value; 2.1.6.5.3.2.1.1 France NGS Market (Equipment), by Value; 2.1.6.5.3.2.1.1.1 France NGS Market (Equipment, by Company), by Value; 2.1.6.5.3.2.1.2 France NGS Market (Equipment), by Volume; 2.1.6.5.4 Italy; 2.1.6.5.4.1 Market Dynamics; 2.1.6.5.4.2 Market Sizing and Forecast, by Value; 2.1.6.5.4.2.1 Italy NGS Market (by Offering), by Value; 2.1.6.5.4.2.1.1 Italy NGS Market (Equipment), by Value; 2.1.6.5.4.2.1.1.1 Italy NGS Market (Equipment, by Company), by Value; 2.1.6.5.4.2.1.2 Italy NGS Market (Equipment), by Volume; 2.1.6.5.5 Spain; 2.1.6.5.5.1 Market Dynamics; 2.1.6.5.5.2 Market Sizing and Forecast, by Value; 2.1.6.5.5.2.1 Spain NGS Market (by Offering), by Value; 2.1.6.5.5.2.1.1 Spain NGS Market (Equipment), by Value; 2.1.6.5.5.2.1.1.1 Spain NGS Market (Equipment, by Company), by Value; 2.1.6.5.5.2.1.2 Spain NGS Market (Equipment), by Volume; 2.1.6.5.6 Rest-of-Europe; 2.1.6.5.6.1 Market Dynamics; 2.1.6.5.6.2 Market Sizing and Forecast, by Value; 2.1.6.5.6.2.1 Rest-of-Europe NGS Market (by Offering), by Value; 2.1.6.5.6.2.1.1 Rest-of-Europe NGS Market (Equipment), by Value; 2.1.6.5.6.2.1.1.1 Rest-of-Europe NGS Market (Equipment, by Company), by Value; 2.1.6.5.6.2.1.2 Rest-of-Europe NGS Market (Equipment), by Volume
3 Markets - Competitive Benchmarking & Company Profiles: 3.1 Competitive Landscape; 3.1.1 Overview; 3.1.2 Corporate Strategies; 3.1.2.1 Mergers and Acquisitions; 3.1.2.2 Synergistic Activities; 3.1.2.3 Business Expansions and Funding; 3.1.3 Business Strategies; 3.1.3.1 Product Launches/Upgradations/Approvals; 3.2 Market Share Analysis; 3.3 Growth-Share Analysis for the NGS Market (by End User); 3.4 Growth-Share Analysis for the NGS Market (by Throughput); 3.5 Company Profiles; 3.5.1 Oxford Nanopore Technologies plc.; 3.5.1.1 Company Overview; 3.5.1.2 Role of Oxford Nanopore Technologies plc. in the NGS Market; 3.5.1.3 Recent Developments; 3.5.1.4 Financials; 3.5.1.5 Target Customers; 3.5.1.6 Analyst Perception; 3.5.2 Qiagen N.V.; 3.5.2.1 Company Overview; 3.5.2.2 Role of Qiagen N.V. in the NGS Market; 3.5.2.3 Financials; 3.5.2.4 Recent Developments; 3.5.2.5 Target Customers; 3.5.2.6 Analyst’s Perspective; 3.5.3 F. Hoffmann-La Roche Ltd; 3.5.3.1 Company Overview; 3.5.3.2 Role of F. Hoffmann-La Roche Ltd in the NGS Market; 3.5.3.3 Financials; 3.5.3.4 Recent Developments; 3.5.3.5 Target Customers; 3.5.3.6 Analyst’s Perspective; 3.5.4 Centogene N.V.; 3.5.4.1 Company Overview; 3.5.4.2 Role of Centogene N.V. in the NGS Market; 3.5.4.3 Financials; 3.5.4.4 Recent Developments; 3.5.4.5 Target Customers; 3.5.4.6 Analyst’s Perspective; 3.6 Emerging Company Snapshots; 3.6.1 Alithea Genomics; 3.6.1.1 Company Overview; 3.6.1.2 Role of Alithea Genomics in the NGS Market; 3.6.1.3 Recent Developments
List of Figures: Figure 1: Europe NGS Market, Impact Analysis; Figure 2: NGS Market (by Region), $Billion, 2022 and 2033; Figure 3: NGS Market Research Methodology; Figure 4: Primary Research Methodology; Figure 5: Bottom-Up Approach (Segment-Wise Analysis); Figure 6: Top-Down Approach (Segment-Wise Analysis); Figure 7: NGS Market, NGS Workflow; Figure 8: NGS Market, NGS Applications; Figure 9: Key Milestones in the Development of Modern-Day NGS Technologies; Figure 10: Europe NGS Market, $Billion, 2022-2033; Figure 11: Workflow of In-Situ Sequencing; Figure 12: Workflow of Microscopy-Based Sequencing; Figure 13: Challenges Associated with Multiplex Sequencing and their Solutions; Figure 14: Key Milestones of the Cancer Genome Atlas Program (TCGA); Figure 15: Key Areas of NGS Application in SARS-CoV-2 Virus Research; Figure 16: NGS Market, Supply Chain Analysis; Figure 17: List of Common Raw Materials and Suppliers in the NGS Market; Figure 18: Number of Research Publications Related to NGS, 2018-2022; Figure 19: Key Primary Insights for the NGS Market; Figure 20: Average Price of NGS Platforms Based on Throughput; Figure 21: NGS Market, Impact Analysis; Figure 22: Cost of Sequencing Human Genome ($), 2001, 2006, and 2021; Figure 23: Estimated Number of New Cancer Cases, Million, 2020, 2030, and 2040; Figure 24: Key Applications of NGS in Clinical Oncology; Figure 25: Some Population-Wide Genome Sequencing Studies in Asia-Pacific; Figure 26: NGS Market, Share of Global Genomic Initiatives in Different Regions (in %); Figure 27: NGS Informatics Market, Genome Sequencing Initiatives in Europe; Figure 28: Key Features of NGS Technology; Figure 29: Comparison of qPCR vs. NGS Technology; Figure 30: Comparison of Microarray vs. NGS Technology; Figure 31: Comparison of Sanger Sequencing vs. NGS Technology; Figure 32: Key Factors Behind Poor Reimbursement of NGS in Clinical Settings; Figure 33: Evolving Regulatory Landscape for Approval of NGS-Based Tests; Figure 34: Key Requirements for Laboratory-Developed Tests (LDTs) as per the IVDR; Figure 35: Europe NGS Market (by Country); Figure 36: Europe NGS Market, $Billion, 2022-2033; Figure 37: Europe NGS Market (by Offering), $Billion, 2022-2032; Figure 38: Europe NGS Market (Equipment), $Billion, 2022-2033; Figure 39: Europe NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 40: Europe NGS Market (Equipment, by Illumina, Inc.), $Million, 2022-2033; Figure 41: Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), $Million, 2022-2033; Figure 42: Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), $Million, 2022-2033; Figure 43: Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), $Million, 2022-2033; Figure 44: Europe NGS Market (Equipment), Units, 2022-2033; Figure 45: Europe NGS Market (by Throughput), $Million, 2022-2033; Figure 46: Europe NGS Market (by Throughput), Units, 2022-2033; Figure 47: Europe NGS Market (by End User), $Billion, 2022-2033; Figure 48: Europe NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033; Figure 49: Europe NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033; Figure 50: Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-20233; Figure 51: Europe NGS Market (Other End Users, by Offering), $Million, 2022-2033; Figure 52: Europe NGS Market (by Technology Type), $Million, 2022-2033; Figure 53: Europe NGS Market (by Application), $Billion, 2022-2033; Figure 54: Europe NGS Market (Application, by Clinical Diagnostics), $Billion, 2022-2033; Figure 55: Europe NGS Market (Application, by Research), $Billion, 2022-2033; Figure 56: Europe NGS Market (by Country), Share (%), 2022 and 2033; Figure 57: Germany NGS Market, $Billion, 2022-2033; Figure 58: Germany NGS Market (by Offering), $Million, 2022-2033; Figure 59: Germany NGS Market (Equipment), $Million, 2022-2033; Figure 60: Germany NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 61: Germany NGS Market (Equipment), Units, 2022-2033; Figure 62: U.K. NGS Market, $Billion, 2022-2033; Figure 63: U.K. NGS Market (by Offering), $Million, 2022-2033; Figure 64: U.K. NGS Market (Equipment), $Million, 2022-2033; Figure 65: U.K. NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 66: U.K. NGS Market (Equipment), Units, 2022-2033; Figure 67: France NGS Market, $Billion, 2022-2033; Figure 68: France NGS Market (by Offering), $Million, 2022-2033; Figure 69: France NGS Market (Equipment), $Million, 2022-2033; Figure 70: France NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 71: France NGS Market (Equipment), Units, 2022-2033; Figure 72: Italy NGS Market, $Billion, 2022-2033; Figure 73: Italy NGS Market (by Offering), $Million, 2022-2033; Figure 74: Italy NGS Market (Equipment), $Million, 2022-2033; Figure 75: Italy NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 76: Italy NGS Market (Equipment), Units, 2022-2033; Figure 77: Spain NGS Market, $Billion, 2022-2033; Figure 78: Spain NGS Market (by Offering), $Million, 2022-2033; Figure 79: Spain NGS Market (Equipment), $Million, 2022-2033; Figure 80: Spain NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 81: Spain NGS Market (Equipment), Units, 2022-2033; Figure 82: Rest-of-Europe NGS Market, $Billion, 2022-2033; Figure 83: Rest-of-Europe NGS Market (by Offering), $Million, 2022-2033; Figure 84: Rest-of-Europe NGS Market (Equipment), $Million, 2022-2033; Figure 85: Rest-of-Europe NGS Market (Equipment, by Company), $Million, 2022-2033; Figure 86: Rest-of-Europe NGS Market (Equipment), Units, 2022-2033; Figure 87: Share of Key Developments, January 2019-May 2023; Figure 88: Number of Mergers and Acquisitions (by Company), January 2019-May 2023; Figure 89: Share of Synergistic Activities (by Company), January 2019-May 2023; Figure 90: Number of Business Expansions and Funding Activities (by Company), January 2019-May 2023; Figure 91: Share of Product Launches/Upgradations/Approvals (by Company), January 2019-May 2023; Figure 92: Market Share Analysis for NGS Market (by Company), 2022; Figure 93: Growth-Share Analysis for the NGS Market (by End User), 2022; Figure 94: Growth-Share Analysis for the NGS Market (by Throughput), 2022; Figure 95: Share of Companies Profiled; Figure 96: Oxford Nanopore Technologies plc.: Overall Product Portfolio; Figure 97: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2020-2022; Figure 98: Oxford Nanopore Technologies plc.: Segment Revenue, $Million, 2020-2022; Figure 99: Oxford Nanopore Technologies plc.: Net Revenue (by Region), $Million, 2020-2022; Figure 100: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2020-2022; Figure 101: Qiagen N.V.: Overall Product Portfolio; Figure 102: Qiagen N.V.: Overall Financials, $Million, 2020-2022; Figure 103: Qiagen N.V.: Segment Revenue, $Million, 2020-2022; Figure 104: Qiagen N.V.: Net Revenue (by Region), $Million, 2020-2022; Figure 105: Qiagen N.V.: R&D Expenditure, $Million, 2020-2022; Figure 106: F. Hoffmann-La Roche Ltd: Overall Product Portfolio; Figure 107: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022; Figure 108: F. Hoffmann-La Roche Ltd: Segment Revenue, $Million, 2020-2022; Figure 109: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022; Figure 110: Centogene N.V.: Overall Product Portfolio; Figure 111: Centogene N.V.: Overall Financials, $Million, 2021-2022; Figure 112: Centogene N.V.: Segment Revenue, $Million, 2021-2022; Figure 113: Centogene N.V.: Net Revenue (by Region), $Million, 2021-2022; Figure 114: Centogene N.V.: R&D Expenditure, $Million, 2021-2022; Figure 115: Alithea Genomics: Overall Product Portfolio
List of Tables: Table 1: Key Questions Answered in the Report; Table 2: Key Features of Short-Read vs. Long-Read Sequencing; Table 3: Comparison of Key NGS Technologies; Table 4: Some Approved NGS Panels for IVD Use; Table 5: Listed Prices of Key NGS Platforms; Table 6: Clinical NGS-Based Assays for Oncology Offerings by Companies; Table 7: Genome Sequencing Projects in Latin America and the Middle East; Table 8: Status of NGS Reimbursement in Europe; Table 9: Few of the Multi-Gene NGS Panels Available in the Market; Table 10: Legal Requirements and Framework in Europe; Table 11: Europe NGS Market, Impact Analysis; Table 12: Some of the Key Distributors in Europe (by Company); Table 13: Genome Projects (by Country)